LFCR News & Events

Lifecore announced that it has signed two CDMO manufacturing service agreements with an existing U.S. biopharmaceutical customer. This customer is a publicly traded U.S.-based pharmaceutical company that has successfully developed multiple marketed products, and continues to advance a pipeline toward commercialization. One of the agreements is a commercial site transfer under which Lifecore will manufacture a currently marketed product that, until now, has been produced by another CDMO. While this agreement has been signed with an existing customer, this is a new product to Lifecore. The company will perform technical transfer services including process performance qualification batches at commercial scale. Upon successful completion of all regulatory requirements, the agreement calls for Lifecore to initiate commercial manufacture of this product. The second agreement with the same existing customer provides for the expansion of services. Lifecore currently manufactures this commercial product for the treatment of ophthalmic-related diseases in one format and will now begin to manufacture it in a second delivery system. This additional delivery modality is currently manufactured in Europe.

Lifecore announced that it has signed a CDMO manufacturing services agreement with a new aesthetics customer for an established, market-approved product. Under the terms of the agreement, Lifecore will perform technical transfer services including process performance qualification batches for a sterile product that the customer currently manufactures in-house, outside the U.S. Initial outsourced manufacturing aims to increase production for products sold in the U.S. market. Lifecore believes the product may generate commercial revenue within 24 months, contributing to the company's targeted 2029 revenue CAGR of 12%. This is the third commercial site transfer Lifecore has signed since October 2025, demonstrating the successful execution of the company's strategic plan to secure lower risk, late-stage programs and site transfers which typically provide a faster and more predictable path to commercial revenue compared to traditional development programs. It is also an example of the company's service expansion into new therapeutic modalities.